

A detailed three-dimensional structure of rifampicin bound to a core bacterial RNA polymerase (Rif-RNAP) is provided. Crystals of the Rif-RNAP are also included in the invention. The present invention further provides procedures for identifying agents that can inhibit bacterial proliferation through the use of rational drug design predicated on the crystals and crystallographic data disclosed.